Revenue has been highly volatile and partner-dependent, with quarterly results ranging from -$16.5M to $32.9M, while the 100% gross margin reflects a licensing profile and operating margins remained negative at -3.2% in 2026Q2 against a net loss of $34.7M.
Nanobiotix S.A. (NBTX) annual income statement — 15-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 18.71M | 29.64M | -7.19M | 36.21M | 4.78M | 2.65M | 2.33M | 2.54M | 3.48M | 3.72M | 5.42M | 4.02M | 2.77M | 1.6M | 970.61K | 1.36M |
| Revenue Growth % | - | 512.28% | -119.86% | 658.12% | 80.43% | 13.85% | -8.5% | -26.96% | -6.53% | -31.35% | 35.03% | 44.91% | 73.67% | 64.38% | -28.65% | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 18.71M | 29.64M | -7.19M | 36.21M | 4.78M | 2.65M | 2.33M | 2.54M | 3.48M | 3.72M | 5.42M | 4.02M | 2.77M | 1.6M | 970.61K | 1.36M |
| Gross Margin % | - | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | 512.28% | -119.86% | 658.12% | 80.43% | 13.85% | -8.5% | -26.96% | -6.53% | -31.35% | 35.03% | 44.91% | 73.67% | 64.38% | -28.65% | - |
| Operating Expenses | 92.2M | 40.46M | 61.2M | 62.99M | 51.48M | 55.23M | 38.75M | 49.32M | 33.55M | 28.99M | 27.28M | 21.16M | 12.39M | 9.77M | 6.15M | 5.23M |
| OpEx % of Revenue | - | 136.49% | -851.21% | 173.96% | 1077.85% | 2086.36% | 1666.8% | 1940.97% | 964.24% | 778.86% | 503.1% | 526.92% | 447.18% | 612.67% | 633.18% | 384.27% |
| Selling, General & Admin | 40.58M | 20.22M | 20.53M | 22.05M | 17.86M | 19.43M | 14.61M | 18.91M | 12.65M | 11.26M | 10.36M | 7.25M | 4.31M | 3.75M | 1.81M | 1.3M |
| SG&A % of Revenue | - | 68.22% | -285.49% | 60.9% | 373.89% | 734.19% | 628.43% | 744.16% | 363.7% | 302.39% | 191.11% | 180.69% | 155.73% | 234.99% | 186.63% | 95.56% |
| Research & Development | 53.49M | 23.11M | 40.54M | 38.4M | 32.64M | 30.38M | 24.33M | 30.41M | 20.89M | 17.73M | 16.92M | 13.9M | 8.08M | 6.03M | 4.31M | 5.21M |
| R&D % of Revenue | - | 77.98% | -563.85% | 106.04% | 683.33% | 1147.64% | 1046.45% | 1196.81% | 600.55% | 476.44% | 312% | 346.23% | 291.46% | 377.67% | 444.26% | 383.2% |
| Other Operating Expenses | 5.3K | -2.88M | 134K | 2.54M | 985K | 5.41M | -188K | 0 | 0 | 1K | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -73.48M | -10.82M | -68.39M | -26.78M | -46.7M | -52.58M | -36.43M | -46.78M | -30.07M | -25.27M | -21.85M | -17.14M | -9.62M | -8.18M | -5.15M | -5.23M |
| Operating Margin % | - | -36.49% | 951.21% | -73.96% | -977.85% | -1986.36% | -1566.8% | -1840.97% | -864.24% | -678.86% | -403.1% | -426.92% | -347.18% | -512.67% | -530.89% | -384.27% |
| Operating Income Growth % | - | 84.18% | -155.39% | 42.66% | 11.18% | -44.34% | 22.13% | -55.58% | -19% | -15.61% | -27.49% | -78.19% | -17.61% | -58.74% | 1.42% | - |
| EBITDA | -70.24M | -9.32M | -66.77M | -25.27M | -45.2M | -51.02M | -34.67M | -45.01M | -29.45M | -24.78M | -21.37M | -16.69M | -9.31M | -7.95M | -5.01M | -5.03M |
| EBITDA Margin % | - | -31.45% | 928.66% | -69.78% | -946.44% | -1927.43% | -1491.35% | -1771.43% | -846.45% | -665.72% | -394.2% | -415.56% | -336.08% | -498% | -515.79% | -369.74% |
| EBITDA Growth % | - | 86.04% | -164.27% | 44.1% | 11.4% | -47.14% | 22.97% | -52.85% | -18.85% | -15.94% | -28.09% | -79.18% | -17.2% | -58.71% | 0.46% | - |
| D&A (Non-Cash Add-back) | 3.24M | 1.5M | 1.62M | 1.51M | 1.5M | 1.56M | 1.75M | 1.77M | 619K | 489K | 482.79K | 456.08K | 307.56K | 233.93K | 146.53K | 197.62K |
| EBIT | -78.39M | -13.56M | -68.26M | -24.24M | -45.72M | -47.16M | -36.62M | -46.78M | -30.07M | -25.27M | -21.85M | -17.14M | -9.62M | -8.18M | -5.15M | -5.22M |
| Net Interest Income | -23.47M | -9.41M | -5.46M | -6.76M | -5.58M | -699.49K | -333K | -4.55M | -726K | -60K | 130.29K | 160.5K | 150.48K | 36.16K | -76.96K | -19.24K |
| Interest Income | 1.67M | 985K | 2.63M | 1.22M | 256K | 0 | 0 | 105K | 34K | 33.03K | 59.49K | 183.22K | 196.65K | 59.06K | 46 | 11.53K |
| Interest Expense | 25.14M | 10.39M | 8.09M | 7.98M | 5.84M | 699.49K | 333K | 4.79M | 847K | 108.37K | 102.2K | 59.52K | 55.73K | 24.57K | 77K | 30.77K |
| Other Income/Expense | -31.05M | -13.14M | 361K | -12.8M | -10.33M | 5.58M | 2.85M | -4.13M | -278K | -876K | 64.61K | 138.56K | 142.52K | 34.5K | -99.18K | -19.34K |
| Pretax Income | -104.53M | -23.96M | -68.03M | -39.58M | -57.03M | -47M | -33.58M | -50.91M | -30.34M | -26.14M | -21.79M | -17M | -9.48M | -8.14M | -5.25M | -5.25M |
| Pretax Margin % | - | -80.82% | 946.19% | -109.31% | -1194.12% | -1775.52% | -1444.34% | -2003.62% | -872.23% | -702.39% | -401.91% | -423.47% | -342.04% | -510.5% | -541.1% | -385.69% |
| Income Tax | -24K | 3K | 101K | 120K | 10K | 5K | 9K | 3K | 0 | 0 | 90.42K | 0 | 79.27K | 0 | 78.89K | 30.67K |
| Effective Tax Rate % | 0.02% | -0.01% | -0.15% | -0.3% | -0.02% | -0.01% | -0.03% | -0.01% | 0% | 0% | -0.41% | 0% | -0.84% | 0% | -1.5% | -0.58% |
| Net Income | -104.97M | -23.96M | -68.13M | -39.7M | -57.04M | -47M | -33.59M | -50.91M | -30.34M | -26.14M | -21.88M | -17M | -9.56M | -8.14M | -5.33M | -5.25M |
| Net Margin % | - | -80.83% | 947.59% | -109.64% | -1194.33% | -1775.71% | -1444.73% | -2003.74% | -872.23% | -702.39% | -403.58% | -423.47% | -344.9% | -510.5% | -549.23% | -385.69% |
| Net Income Growth % | - | 64.83% | -71.62% | 30.4% | -21.36% | -39.93% | 34.03% | -67.79% | -16.07% | -19.48% | -28.69% | -77.92% | -17.33% | -52.79% | -1.61% | - |
| Net Income (Continuing) | -104.51M | -23.96M | -68.13M | -39.7M | -57.04M | -47M | -33.59M | -50.91M | -30.34M | -26.14M | -21.88M | -17M | -9.56M | -8.14M | -5.33M | -5.25M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | - | -0.50 | -1.44 | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| EPS Growth % | - | 65.28% | -33.33% | 34.15% | -21.48% | 2.17% | 41.28% | -54.61% | -1.33% | -4.9% | -19.17% | -62.16% | 2.63% | -16.92% | 80.99% | - |
| EPS (Basic) | - | -0.50 | -1.44 | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| Diluted Shares Outstanding | 48.88M | 47.82M | 47.27M | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.63M | 17.48M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
| Basic Shares Outstanding | 48.88M | 47.82M | 47.27M | 36.76M | 34.85M | 34.73M | 24.39M | 21.63M | 19.62M | 17.43M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying NBTX stock.
For fiscal year 2025, Nanobiotix S.A. (NBTX) reported total revenue of $29.6M. This represents a 2079.1% increase compared to $1.4M in 2011.
Nanobiotix S.A. (NBTX) reported a net loss of $24.0M for the fiscal year ending 2025.
Nanobiotix S.A. (NBTX) reported an operating income of $-10.8M, resulting in an operating profit margin of -36.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Nanobiotix S.A. (NBTX) generated $29.6M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Milestone-dependent revenue concentration
Lumpy Milestone Revenue Drives Growth
According to the reported income statement, NBTX's quarterly revenue swings from $32.9M in 2023Q4 to negative $16.5M in 2024Q4, indicating that top-line results are driven by irregular partner-linked recognition rather than a steady commercial run-rate.
The quarterly series shows revenue alternating between large recognition events and near-zero or negative periods, which suggests collaboration accounting rather than organic demand is shaping the line. The reported 512% trailing growth therefore reflects a favorable comparison base more than a durable acceleration. Investors should treat the trend as non-representative until revenue stabilizes across several consecutive quarters.
Full Gross Margin Reflects Licensing Economics
Based on reported figures, NBTX's 100% gross margin across all ten quarters, with zero reported COGS, reflects a licensing revenue profile rather than a product-margin structure, leaving the margin signal uninformative about future manufacturing economics.
Because no cost of goods sold is recorded, gross margin carries no information about pricing power or unit economics. The relevant margin signal is the operating line, which has remained negative in nearly every period. Any future physical product would likely introduce variable production costs that the current figures do not yet reflect.
Fixed R&D Base Swamps Revenue Volatility
As reflected in the 2026Q2 figures, NBTX's R&D expense of $11.8M and SG&A of $10.7M exceeded revenue of $5.6M, producing an operating loss of $17.9M and an operating margin of -3.2% on a quarterly basis.
R&D and SG&A have remained in a relatively stable band while revenue has oscillated, so operating results are determined primarily by the timing of top-line recognition. This negative operating leverage suggests that revenue growth alone will not restore profitability unless it scales well beyond the current expense base. Monitoring whether operating losses narrow as revenue normalizes will be the clearest test of structural progress.
Net Losses Exceed Operating Losses
Based on EDBL-style reported figures, NBTX posted a 2026Q2 net loss of $34.7M against an operating loss of $17.9M, a gap that warrants further investigation into non-operating items reported below operating income.
The difference between operating and net loss in several quarters is large enough that non-operating charges, financing costs, or tax effects may be contributing materially. Stock-based compensation of up to $2.4M per quarter also affects reported earnings. The reported EPS trajectory should be read with these items in mind rather than as a clean measure of operating performance.
R&D Dominates a Development-Stage Cost Base
According to reported quarterly figures, NBTX's R&D spending ranged from roughly $8.6M to $22.0M across the ten quarters, making it the dominant cost line and the primary determinant of cash consumption.
R&D consistently exceeds SG&A, consistent with a clinical-stage program carrying multiple trials at once. Expense discipline is hard to judge from the income statement alone because trial timing drives quarterly variation. Investors should watch whether R&D declines as enrollment completes or remains elevated as programs advance.
Revenue Quality Could Prove Non-Recurring
Based on the reported figures, the 512% revenue growth and 100% gross margin could be misread as commercial traction, while the underlying pattern of swinging and negative quarters suggests the revenue base may be non-recurring and partner-dependent.
A bear reading would emphasize that negative quarterly revenue and a persistent operating loss are inconsistent with a scalable commercial business. If milestone recognition slows, the top line could compress sharply against a largely fixed expense base. This analysis is an inference from the reported pattern and does not establish the terms or durability of any specific partner arrangement.